List of Excipients in Branded Drug PROCAINAMIDE HYDROCHLORIDE

Generic Drugs Containing PROCAINAMIDE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Henry Schein Inc	procainamide hydrochloride	0404-9939	HYDROCHLORIC ACID
Henry Schein Inc	procainamide hydrochloride	0404-9939	METHYLPARABEN
Henry Schein Inc	procainamide hydrochloride	0404-9939	SODIUM HYDROXIDE
Henry Schein Inc	procainamide hydrochloride	0404-9939	SODIUM METABISULFITE
Henry Schein Inc	procainamide hydrochloride	0404-9939	WATER
Hospira Inc	procainamide hydrochloride	0409-1902	HYDROCHLORIC ACID
Hospira Inc	procainamide hydrochloride	0409-1902	METHYLPARABEN

What are the Most Frequently-Used Excipients in PROCAINAMIDE HYDROCHLORIDE?

# Of NDCs	Excipient
4	BENZYL ALCOHOL
16	HYDROCHLORIC ACID
12	METHYLPARABEN
4	SODIUM BISULFITE
16	SODIUM HYDROXIDE
12	SODIUM METABISULFITE
12	WATER

Procainamide Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

Procainamide hydrochloride is an off-patent Class IA antiarrhythmic with commercial opportunity concentrated in hospital injectables, differentiated oral modified-release products, and supply-reliable formulations. The active ingredient has limited protection from patents or regulatory exclusivity. Competitive advantage therefore depends on excipient selection, preservative strategy, container closure, stability, manufacturing reliability, and targeted hospital procurement.

What is the commercial status of procainamide hydrochloride?

Procainamide hydrochloride is approved for the treatment of cardiac arrhythmias, including ventricular arrhythmias and certain atrial rhythm disorders. It is marketed in oral and parenteral dosage forms, although availability varies by country and product presentation.

The principal commercial constraints are:

• Low-volume use relative to modern antiarrhythmics.
• Hospital-driven demand for injectable products.
• Generic pricing pressure.
• Complex stability and packaging requirements for sterile solutions.
• Narrow clinical use and declining routine use compared with amiodarone, lidocaine, sotalol, and other alternatives.

Procainamide hydrochloride remains commercially relevant in acute-care settings because it can be used for selected ventricular and supraventricular arrhythmias and is included in emergency and advanced cardiac life-support treatment frameworks. The American Heart Association identifies intravenous procainamide as an option in selected tachyarrhythmia settings, subject to clinical contraindications and infusion limitations.[1]

Dosage forms and commercial segments

Segment	Typical use	Commercial attractiveness	Main development issue
IV injection	Emergency and inpatient arrhythmia treatment	Moderate	Sterility, stability, ready-to-use presentation
IV infusion concentrate	Hospital dilution before administration	Moderate	Dilution compatibility and dosing workflow
Immediate-release tablets or capsules	Chronic oral therapy	Low to moderate	Generic price competition
Extended-release tablets	Maintenance therapy	Moderate	Controlled-release performance and bioequivalence
Premixed infusion bag or syringe	Emergency department and intensive care	High relative opportunity	Device, stability, and packaging validation
Compounded or extemporaneous products	Supply-constrained settings	Opportunistic	Regulatory and quality-control risk

What patents protect procainamide hydrochloride products?

Procainamide hydrochloride is an established small-molecule drug with no meaningful composition-of-matter patent barrier for current development. The original drug patents and early product patents expired decades ago.

The commercial IP position is therefore different from that of a recently approved drug:

IP category	Current relevance
Composition-of-matter patents	No meaningful remaining protection expected
Basic formulation patents	Historical patents are generally expired
Extended-release formulation patents	Potentially relevant only if a new formulation has unexpired claims
Manufacturing patents	Possible but difficult to enforce unless process-specific and commercially material
Method-of-use patents	Limited opportunity because core antiarrhythmic uses are established
Device and packaging patents	Potentially available for proprietary delivery systems
Trade secrets	Important for process controls, impurity management, and stability programs

The United States Food and Drug Administration’s Orange Book is the primary source for listed patents and exclusivity associated with approved drug products.[2] For an old generic active ingredient such as procainamide hydrochloride, the principal launch risk is normally regulatory execution and market economics rather than an innovator patent challenge.

When does procainamide hydrochloride lose exclusivity?

Procainamide hydrochloride has already lost meaningful market exclusivity in the United States. It is not an NCE-stage product and does not carry the commercial profile of a drug protected by five years of new chemical entity exclusivity.

Relevant exclusivity categories include:

• NCE exclusivity: not applicable to the historical active ingredient.
• Orphan-drug exclusivity: not a general feature of procainamide hydrochloride products.
• Pediatric exclusivity: product-specific and not a durable protection strategy for the molecule.
• Three-year clinical-investigation exclusivity: potentially relevant only to a newly approved formulation or indication supported by qualifying investigations.
• Five-year new-product exclusivity under a 505(b)(2) pathway: possible for a genuinely new formulation or delivery system, but not for ordinary generic duplication.

A new product could obtain limited regulatory exclusivity if it introduces a distinct dosage form, delivery system, or clinically supported formulation. That protection would not restore exclusivity to the active ingredient itself.

How many patents cover procainamide hydrochloride formulations?

The number of practically relevant patents is likely small. The strongest opportunity is not a broad patent on procainamide hydrochloride but a narrow claim set directed to a specific formulation, release profile, container, or administration method.

Potential claim categories include:

1. Extended-release matrices that control procainamide release over a defined period.
2. Stable aqueous injectable solutions with specified pH and impurity limits.
3. Preservative-free single-dose presentations.
4. Ready-to-administer IV bags or syringes.
5. Low-extractables container closure systems.
6. Compatibility with infusion diluents and administration sets.
7. Taste-masked oral liquids or dispersible products.
8. Manufacturing processes that reduce degradation products.

Patent strength depends on whether the claims cover a measurable technical result. A claim directed only to routine selection of common excipients is vulnerable to obviousness and lack-of-enablement challenges. Stronger protection would require comparative stability, dissolution, impurity, or usability data showing an unexpected result.

What excipients are suitable for procainamide hydrochloride tablets and capsules?

Procainamide hydrochloride is a water-soluble salt. Immediate-release oral products can use conventional excipient systems with relatively limited formulation complexity.

Immediate-release oral strategy

A standard tablet or capsule may use:

• Microcrystalline cellulose as a diluent and compression aid.
• Lactose monohydrate or mannitol as a filler.
• Povidone as a binder.
• Croscarmellose sodium or sodium starch glycolate as a disintegrant.
• Colloidal silicon dioxide as a glidant.
• Magnesium stearate or sodium stearyl fumarate as a lubricant.
• Hypromellose or similar film former for coating.
• Titanium dioxide and approved colorants where required.

The principal development concern is not drug release but manufacturability, content uniformity, tablet robustness, moisture control, and dissolution consistency. The FDA Inactive Ingredient Database can support excipient selection by identifying prior use in approved dosage forms and routes.[3]

Extended-release strategy

Extended-release products offer greater differentiation than immediate-release generics. Possible systems include:

• Hydrophilic hypromellose matrices.
• Polyethylene oxide matrices.
• Insoluble acrylic or cellulose-based coatings.
• Multiparticulate pellets filled into capsules.
• Osmotic delivery systems.
• Ion-exchange resin complexes.

A hydrophilic matrix is likely to offer the most practical balance of development cost and manufacturability. An osmotic system may provide stronger differentiation but would require a more substantial device-formulation program and a more demanding in vitro-in vivo correlation strategy.

The design target should be a controlled plasma profile that reduces dosing frequency without producing dose dumping. Alcohol-induced dose-dumping studies, food-effect studies, dissolution testing across pH conditions, and abuse-deterrence assessments may be relevant depending on the product design.

What excipients are suitable for procainamide hydrochloride injections?

Parenteral products have the clearest near-term commercial opportunity because hospitals value operational simplicity and reliable supply.

A conventional aqueous injection may use:

• Water for Injection as the vehicle.
• Hydrochloric acid or sodium hydroxide for pH adjustment.
• Sodium chloride for tonicity adjustment where required.
• A permitted antimicrobial preservative for multidose presentations, if justified.
• Nitrogen overlay or oxygen-controlled filling where oxidation risk warrants it.

The formulation should minimize excipient count. Every additional excipient increases the burden for compatibility, extractables and leachables, toxicology, and stability assessment.

Preservative-free versus multidose design

A preservative-free single-dose vial, ampoule, or prefilled syringe is generally more attractive for emergency use. It reduces preservative exposure and simplifies bedside administration. The tradeoff is higher packaging and fill-finish cost.

A multidose vial may reduce unit cost but introduces:

• Preservative qualification.
• Container puncture and in-use stability requirements.
• Greater risk of medication-use errors.
• More complex hospital handling requirements.

For a low-volume emergency drug, the commercial value of a preservative-free presentation may exceed the manufacturing savings from a multidose format.

Ready-to-use infusion products

A premixed infusion bag or ready-to-use syringe can create differentiation without changing the active ingredient. Potential benefits include:

• Reduced preparation time.
• Lower pharmacy compounding burden.
• Fewer dilution errors.
• Standardized concentration.
• Improved emergency-department workflow.
• Greater suitability for automated dispensing systems.

Candidates include flexible IV bags, polymer syringes, and dual-chamber systems. The formulation must be evaluated for adsorption, precipitation, pH drift, discoloration, container permeability, and compatibility with common infusion solutions and administration sets.

What FDA regulatory pathway applies to new procainamide products?

An ordinary tablet, capsule, or injection that is pharmaceutically equivalent to an approved reference product would generally use an Abbreviated New Drug Application under section 505(j) of the Federal Food, Drug, and Cosmetic Act.[4]

A differentiated formulation may require a 505(b)(2) application when approval relies partly on FDA findings for an existing product but includes new clinical, pharmacokinetic, formulation, or delivery-system information.

Likely regulatory pathway by product

Product concept	Likely pathway
Conventional generic injection	ANDA
Conventional immediate-release tablet	ANDA
Generic extended-release product	ANDA if reference product and bioequivalence pathway exist
New extended-release technology	505(b)(2) or complex ANDA
Premixed infusion bag	ANDA or 505(b)(2), depending on reference and formulation changes
Prefilled syringe	505(b)(2) or combination-product review issues may arise
New indication	505(b)(2) with clinical support

A 505(b)(2) strategy may provide a more defensible commercial position, but it carries higher development and clinical risk than a standard ANDA.

What Orange Book status and Paragraph IV risks apply?

The Orange Book identifies approved drug products, therapeutic equivalence evaluations, patents, and exclusivity information.[2] For a legacy procainamide hydrochloride product, an applicant pursuing a standard generic strategy would usually face limited innovator patent risk.

Potential Paragraph IV issues arise only if an applicant files against an approved reference product with a listed patent. The practical risk depends on:

• Whether the reference product has active listed patents.
• Whether the product is a conventional or modified-release dosage form.
• Whether a new formulation patent is listed.
• Whether the applicant uses a Paragraph IV certification.
• Whether the reference sponsor files infringement litigation within the statutory period.

For a new formulation, patent risk shifts from the historical active ingredient to the new product’s formulation and delivery claims. A company seeking to commercialize a differentiated product should assume that any valuable release technology or device integration may attract patent filings from competing developers.

No broad biosimilar pathway applies. Procainamide hydrochloride is a small molecule, so the relevant competitive pathways are ANDA and 505(b)(2), not abbreviated biologics applications.

Which companies are challenging procainamide hydrochloride products?

Competition is likely to come from generic manufacturers, hospital injectable suppliers, contract manufacturers, and specialty pharmaceutical companies rather than from a single branded innovator.

The competitive field includes:

• Established generic oral-drug manufacturers.
• Sterile injectable manufacturers.
• Contract development and manufacturing organizations.
• Specialty suppliers serving hospital formularies.
• Companies developing premixed emergency medicines.
• Regional manufacturers supplying markets with limited product availability.

The key competitive variable is product availability. A manufacturer with dependable sterile capacity, validated packaging, and a stable supply of active pharmaceutical ingredient may outperform a lower-cost competitor that experiences manufacturing interruptions.

What patent litigation and settlement agreements affect procainamide hydrochloride?

Procainamide hydrochloride is unlikely to generate significant current patent litigation over the basic molecule. The original commercial products are old, and the central active-ingredient patents have expired.

For a newly developed formulation, litigation could arise over:

• Release-control polymers.
• Multiparticulate coating systems.
• Premixed infusion concentrations.
• Prefilled syringe architecture.
• Container closure and stability claims.
• New clinical use claims.

No material current settlement framework is associated with the historical procainamide hydrochloride molecule in the cited FDA materials. Any future settlement would likely concern a new formulation sponsor and a generic applicant rather than the legacy active ingredient.

How strong is the patent estate for procainamide hydrochloride?

The legacy patent estate is weak. A new commercial program can create a stronger but narrow estate through formulation and delivery claims.

Patent factor	Assessment
Active ingredient protection	Very weak or expired
Conventional oral formulation	Weak
Conventional injectable formulation	Weak to moderate if stability data are specific
Extended-release technology	Moderate if supported by unexpected performance
Ready-to-use delivery	Moderate, especially with device and compatibility claims
Manufacturing process	Moderate where impurity control is difficult to replicate
Method of use	Weak for established indications
Trade-secret protection	Moderate for process and impurity-control know-how

The most defensible strategy is a layered portfolio combining composition claims, process claims, container claims, and method-of-use claims. Patent filings should be supported by comparative data rather than routine excipient substitutions.

What commercial opportunities exist for procainamide hydrochloride?

1. Hospital shortage replacement

Supply reliability is the clearest opportunity. A manufacturer can compete through:

• Multiple approved fill-finish sites.
• Long-term API sourcing.
• Longer dating periods.
• Small and large vial configurations.
• Barcode and automated-dispensing compatibility.
• Transparent hospital supply commitments.

2. Ready-to-administer injectable products

A premixed bag or syringe can command a premium over a conventional vial if it reduces pharmacy labor and administration risk. The product should target emergency departments, intensive-care units, cardiac catheterization centers, and transport services.

3. Preservative-free packaging

Preservative-free single-dose formats may attract hospitals seeking simpler medication handling and lower excipient exposure. Plastic syringes and unit-dose vials offer practical differentiation.

4. Extended-release oral product

An extended-release formulation could compete on dosing convenience. The opportunity is limited by the size of the chronic-use population and the need to establish bioequivalence or clinical comparability.

5. Regional and international supply

Markets with limited access to sterile antiarrhythmics may provide better margins than the highly competitive U.S. generic market. Geographic strategy must account for local registration, pharmacopoeial standards, serialization, and procurement systems.

How does procainamide hydrochloride compare with competing antiarrhythmics?

Drug	Main commercial advantage	Excipient opportunity	Competitive pressure
Procainamide HCl	Established IV and oral use	Premix, preservative-free injection, ER oral	Low price, limited volume
Amiodarone HCl	Broad acute-care use	Solubilization and infusion compatibility	High clinical and generic competition
Lidocaine HCl	Familiar emergency injectable	Ready-to-use and premix products	High
Sotalol HCl	Oral rhythm control	Controlled-release and tablet optimization	Moderate
Flecainide acetate	Oral rhythm control	Modified release and patient convenience	Moderate
Quinidine	Limited modern use	Niche formulation opportunity	Low volume

Procainamide’s advantage is a relatively uncomplicated active ingredient from a formulation perspective. Its disadvantage is limited demand and strong substitution by other antiarrhythmic therapies.

What generic launch scenarios exist for procainamide hydrochloride?

Base case: conventional generic launch

A conventional injection or immediate-release oral product can launch with limited patent risk but may face low margins. Success depends on supply continuity, manufacturing cost, and inclusion in hospital purchasing contracts.

Upside case: differentiated hospital presentation

A ready-to-use syringe, premixed infusion, or preservative-free unit-dose product can support higher pricing and reduce direct substitution. This route requires stronger stability and packaging data.

Higher-risk case: extended-release reformulation

An extended-release product may obtain greater differentiation and potentially a 505(b)(2) regulatory position. Development costs, bioequivalence risk, clinical adoption, and payer acceptance are higher.

Geographic launch

A regional launch can target countries where procainamide remains clinically used but injectable supply is inconsistent. The principal barriers are local regulatory requirements and procurement scale, not originator patent rights.

Key Takeaways

• Procainamide hydrochloride has no meaningful remaining composition-of-matter exclusivity.
• The strongest commercial opportunity is in sterile hospital products, not ordinary tablets.
• Preservative-free vials, prefilled syringes, and premixed infusion bags offer the clearest formulation differentiation.
• Extended-release oral products may support a 505(b)(2) strategy but require greater development investment.
• Patent value will come from formulation, packaging, manufacturing, and delivery claims.
• Biosimilar risk is irrelevant because procainamide hydrochloride is a small molecule.
• Paragraph IV and settlement risk is likely limited for legacy products but can arise around new formulation patents.
• Revenue opportunity is constrained by low overall volume, so hospital contracting and supply reliability are central to the business case.
• Excipient selection should prioritize sterile compatibility, stability, impurity control, and workflow reduction over novelty alone.

FAQs About Procainamide Hydrochloride Formulation and Market Entry

Can procainamide hydrochloride be formulated as a preservative-free injection?

Yes. A single-dose vial, ampoule, or prefilled syringe can avoid antimicrobial preservatives, provided sterility assurance, container closure integrity, stability, and particulate controls are validated.

Is procainamide hydrochloride suitable for a pediatric liquid formulation?

It can be developed as an oral liquid, but palatability, dose uniformity, microbiological preservation, and storage stability require specific evaluation. Pediatric use may create a niche product opportunity where approved liquid alternatives are limited.

Can a new procainamide formulation receive three-year FDA exclusivity?

Potentially, if approval is based on new clinical investigations conducted or sponsored by the applicant and the product meets statutory requirements. The exclusivity would apply to the approved change, not to the underlying active ingredient.

Which excipient is most important in a procainamide extended-release tablet?

The release-controlling polymer is the most commercially important excipient category. Hypromellose and other hydrophilic matrix polymers are practical starting points, but the final choice depends on dose, target release profile, tablet geometry, and food-effect performance.

What is the main manufacturing barrier for procainamide hydrochloride injection?

The principal barrier is reliable sterile manufacturing with validated stability and packaging performance. The active ingredient is not inherently protected by difficult synthesis, but sterile fill-finish capacity and supply continuity can limit competition.

References

1. American Heart Association. (2020). 2020 American Heart Association guidelines for CPR and ECC: Adult advanced life support. Circulation, 142(Suppl. 2), S366-S468.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

3. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

4. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2). Guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/applications-covered-section-505b2)